Summary & Overview

Lymphoma and Non-Acute Leukemia with CC: Inpatient Reimbursement Overview

DRG 841 encompasses admissions for lymphoma and non-acute leukemia with a Complication or Comorbidity, covering inpatient care for disease manifestations, complications, or treatment-related issues. Accurate classification in this Diagnosis-Related Group affects Medicare inpatient reimbursement by reflecting higher resource intensity when Complications or Comorbidities are present.

Lymphoma and Non-Acute Leukemia with CCDRG Lymphoma and Non-Acute Leukemia with CCDRG 841Diagnosis-Related GroupInpatient ReimbursementMedicareHematologyOncologyHospital CodingCase Mix

DRG 841 Overview

DRG 841 covers inpatient admissions for lymphoma and non-acute leukemia when a Complication or Comorbidity is present. This Diagnosis-Related Group captures patients with hematologic malignancies requiring inpatient care for disease-related symptoms, treatment complications, or supportive interventions. It matters for Medicare payment because the presence of a Complication or Comorbidity increases relative resource use and affects assignment to higher-paying Diagnosis-Related Group categories compared with cases without such comorbidities. Payers and hospital coding staff monitor this Diagnosis-Related Group to ensure accurate case mix classification and reimbursement.

National Payment Rates

Across commercial payers the observed rate range for DRG 841 spans from about $370 up to $58K, with the widest spread seen between Anthem (min $390 to max $58K) and other payers. Reference the payer table and the chart below for payer-specific percentiles and distribution. Major payers shown include Blue Cross Blue Shield, UnitedHealth Group, Cigna, Aetna, and Anthem.

Mean Rates by Payer — National — DRG 841

The CMS 2023 data represent national Medicare fee-for-service inpatient payments published under the CMS Provider Utilization and Payment Data program. The table below shows average total payment, average submitted covered charges, average Medicare payment amount, and total discharges for DRG 841. Values reflect national aggregates for Medicare beneficiaries only.

State Payment Rates

State: Alaska1 / 49

Alaska Benchmarks

Alaska’s reimbursement range for DRG 841 spans from $25K to $39K across payers, with Cigna at the top end and Anthem and Blue Cross Blue Shield clustered at the low end. The state’s mean levels are generally higher than some national medians, highlighting a notable upward deviation versus broader national averages. See the table and chart below for the payer-level distribution.

Key Insights for Alaska

Cigna is the highest paying payer in Alaska with a mean of $39K, while Anthem and Blue Cross Blue Shield are the lowest at $25K.
Alaska’s payer range spans from $25K to $39K, a tighter and higher midrange compared with national medians where several national payers show substantially lower medians around $15K–$25K.

Clinical Trials

Trials of novel immunochemotherapy combinations and sequencing strategies for adults with aggressive or relapsed lymphoma and non-acute leukemias: these studies evaluate safety, response rates, progression-free survival, and hematologic recovery when integrating newer targeted agents or immune-based therapies with established chemoimmunotherapy backbones in inpatients who present with bulky disease, high tumor burden, or treatment-related complications. The patient populations typically include hospitalized adults with symptomatic disease, cytopenias, or therapy-refractory lymphoma/leukemia requiring intensive management; results inform inpatient resource use, transfusion needs, and length of stay which are directly relevant to hospital billing and DRG-based reimbursement. - Comparative effectiveness studies of inpatient management strategies for disease- or treatment-related complications (for example febrile neutropenia, tumor lysis syndrome, severe cytopenias, or symptomatic organ infiltration): randomized or pragmatic cohort studies compare different supportive care protocols, antimicrobial stewardship approaches, or transfusion thresholds in patients admitted under this DRG. These trials focus on hospitalized patients at high risk for infectious or metabolic complications and aim to reduce ICU transfers, readmissions, and complication-related costs, providing evidence to optimize protocols that affect payer expenditures and DRG resource intensity. - Post-discharge outcomes and care-transition interventions for patients hospitalized with lymphoma or non-acute leukemia and a complication (CC): interventional or observational studies evaluate discharge planning, early outpatient follow-up models, home-based infusion or monitoring, and readmission-reduction bundles to improve continuity of care, adherence to consolidation therapies, and surveillance for relapse. Enrolling patients recently discharged after an inpatient stay, these studies address readmission rates, outpatient utilization, and long-term survival or quality-of-life metrics, offering data that help providers and payers design value-based care pathways and predict downstream costs associated with this DRG.

Average Total Payment	Average Submitted Charges	Average Medicare Payment	Total Discharges
$16K	$78K	$13K	5.4K

Trials of novel immunochemotherapy combinations and sequencing strategies for adults with aggressive or relapsed lymphoma and non-acute leukemias: these studies evaluate safety, response rates, progression-free survival, and hematologic recovery when integrating newer targeted agents or immune-based therapies with established chemoimmunotherapy backbones in inpatients who present with bulky disease, high tumor burden, or treatment-related complications. The patient populations typically include hospitalized adults with symptomatic disease, cytopenias, or therapy-refractory lymphoma/leukemia requiring intensive management; results inform inpatient resource use, transfusion needs, and length of stay which are directly relevant to hospital billing and DRG-based reimbursement. - Comparative effectiveness studies of inpatient management strategies for disease- or treatment-related complications (for example febrile neutropenia, tumor lysis syndrome, severe cytopenias, or symptomatic organ infiltration): randomized or pragmatic cohort studies compare different supportive care protocols, antimicrobial stewardship approaches, or transfusion thresholds in patients admitted under this DRG. These trials focus on hospitalized patients at high risk for infectious or metabolic complications and aim to reduce ICU transfers, readmissions, and complication-related costs, providing evidence to optimize protocols that affect payer expenditures and DRG resource intensity. - Post-discharge outcomes and care-transition interventions for patients hospitalized with lymphoma or non-acute leukemia and a complication (CC): interventional or observational studies evaluate discharge planning, early outpatient follow-up models, home-based infusion or monitoring, and readmission-reduction bundles to improve continuity of care, adherence to consolidation therapies, and surveillance for relapse. Enrolling patients recently discharged after an inpatient stay, these studies address readmission rates, outpatient utilization, and long-term survival or quality-of-life metrics, offering data that help providers and payers design value-based care pathways and predict downstream costs associated with this DRG.

OpenPayer

Summary & Overview

Lymphoma and Non-Acute Leukemia with CC: Inpatient Reimbursement Overview

DRG 841 Overview

National Payment Rates

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes

Patient Population

State Payment Rates

Alaska Benchmarks

Key Insights for Alaska

Clinical Trials

Related Codes